Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Inogen nets $52.5mm through its IPO

Executive Summary

Inogen Inc. netted $52.5mm through the initial public offering of 3.5mm common shares at $16 each. Existing stockholders also sold 882k shares. Earlier this month the company had hoped to sell 4.4mm shares between $16-18. The twelve-year-old company develops, manufactures, and markets portable oxygen concentrators (POCs) that provide supplemental long-term oxygen to patients with chronic respiratory conditions.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies